Welcome to our dedicated page for Outlook Therapeutics news (Ticker: OTLK), a resource for investors and traders seeking the latest updates and insights on Outlook Therapeutics stock.
Outlook Therapeutics, Inc. develops and commercializes ONS-5010/LYTENAVA, an ophthalmic formulation of bevacizumab for retina diseases, including wet age-related macular degeneration. Company news commonly covers the product’s European Commission and MHRA marketing authorizations, commercial launch activity in Germany, Austria and the UK, and U.S. regulatory communications involving the biologics license application pathway for neovascular AMD.
Updates also include capital-structure actions used to fund operations, such as public offerings, registered direct offerings, warrants, convertible-note amendments and note financing. Governance and shareholder-approval matters appear in connection with securities issuance and authorized-share requirements.
Outlook Therapeutics (OTLK), a biopharmaceutical company specializing in bevacizumab treatments for retina diseases, has announced a proposed public offering of common stock and warrants. The offering will be managed by BTIG, LLC as the sole book-running manager. The company plans to use the proceeds for working capital and general corporate purposes.
The securities will be offered under a previously effective shelf registration statement (Form S-3, No. 333-278340). The final size, terms, and completion of the offering are subject to market conditions and cannot be guaranteed. A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC.
Outlook Therapeutics (Nasdaq: OTLK) announced the FDA's acceptance of their resubmitted Biologics License Application (BLA) for ONS-5010, their ophthalmic formulation of bevacizumab for treating wet age-related macular degeneration (wet AMD). The FDA designated it as a Class 2 review with a PDUFA goal date of August 27, 2025.
If approved, ONS-5010 will be marketed as LYTENAVA™ in the United States and is expected to receive 12 years of regulatory exclusivity. The resubmission includes efficacy and safety data from the NORSE EIGHT trial, along with additional chemistry, manufacturing, and controls information requested by the FDA.
The company has already secured regulatory approval for this treatment in the European Union and United Kingdom, marking it as the first authorized ophthalmic formulation of bevacizumab for wet AMD in these regions.
Outlook Therapeutics (OTLK) has re-submitted its Biologics License Application (BLA) to the FDA for ONS-5010, branded as LYTENAVA™ (bevacizumab-vikg), for treating wet age-related macular degeneration (wet AMD). The resubmission follows the company's recent regulatory approvals in the EU and UK.
The BLA includes data from the NORSE EIGHT trial, a randomized study of 400 wet AMD patients comparing ONS-5010 to ranibizumab. While ONS-5010 showed clinical improvements with 3.3 to 5.5 letter improvement in vision across timepoints, it did not meet the pre-specified non-inferiority endpoint at week 8. However, anatomical response was comparable between treatments, with ONS-5010 achieving a -123.9 micron reduction in central retinal thickness versus -127.3 microns for ranibizumab.
An FDA decision is expected within six months.
Outlook Therapeutics (OTLK) announced its participation in the Virtual Investor 'Top 5 for '25' On-Demand Conference. The company's CFO and Interim CEO, Lawrence A. Kenyon, presented the top five reasons why investors should focus on Outlook Therapeutics in 2025. The presentation is now available for viewing online.
Notably, OTLK is a biopharmaceutical company that has achieved regulatory approval in the European Union and the United Kingdom for its ophthalmic formulation of bevacizumab, marking the first authorized use of such treatment for wet age-related macular degeneration (wet AMD).
Outlook Therapeutics (OTLK) reported financial results for Q1 FY2025 and provided key updates. The company plans to resubmit its ONS-5010 BLA in Q1 2025, with potential FDA approval expected in Q3 2025. Commercial launches of LYTENAVA™ (bevacizumab gamma) are planned for Germany and UK in Q2 2025, marking the first authorized ophthalmic formulation of bevacizumab for wet AMD treatment in these regions.
For Q1 FY2025, OTLK reported net income of $17.4 million ($0.72 per share), compared to a net loss of $11.2 million ($0.86 per share) in the same period last year. The company had cash and cash equivalents of $5.7 million as of December 31, 2024, with additional $17.8 million received in January 2025 from warrant exercises.
In the NORSE EIGHT trial, while ONS-5010 missed the primary endpoint at week 8, it met non-inferiority margins at week 12, showing mean visual acuity improvements and similar anatomical response compared to ranibizumab.
Outlook Therapeutics (OTLK) announced that Dr. Jennifer Kissner, SVP Clinical Development, participated in a Virtual Investor segment to discuss the NORSE EIGHT clinical trial results. The segment focuses on the complete 12-week safety and efficacy data for ONS-5010, their ophthalmic bevacizumab formulation for wet AMD treatment.
The company, which has already secured regulatory approval in the European Union and United Kingdom for the first authorized ophthalmic bevacizumab formulation to treat wet age-related macular degeneration, plans to resubmit its Biologics License Application (BLA) in Q1 2025. NORSE EIGHT represents the second of two adequate and well-controlled clinical trials evaluating ONS-5010 in wet AMD patients.